Abstract
Gilead paused enrollment in trials of its anti-CD47 therapy magrolimab following suspicions of a safety issue experienced by patients with acute myeloid leukemia or myelodysplastic syndrome who received it in combination with the chemotherapeutic agent azacitidine.
©2022 American Association for Cancer Research.
2022
American Association for Cancer Research.
You do not currently have access to this content.